Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by edroseon May 23, 2022 9:59pm
367 Views
Post# 34702734

New study will probably not continue past phase 1-2

New study will probably not continue past phase 1-2They sold plasma division for peanuts few weeks before fda approved our drug  
prometic had excellent results re 4050 in more than one study  and they stopped studies after they wiped out retail investors 
3 years later they haven't done anything to increase shareholders value BUT they gave the Shute compensation packages and sold most assets of company and paid back salp which is Cayman Islands to avoid  paying canadian taxes 
this new study how how often do they treat patients with high ammonia per year in hospitals 
<< Previous
Bullboard Posts
Next >>